title: Adverse effects of therapy for ANCA-associated vasculitis.
abstract: The introduction of cyclophosphamide- and prednisolone-based treatment regimens has significantly improved outcome in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. However, these regimens are nonspecific immunosuppressants associated with significant toxicity, including increased risk of infection, leucopenia, diabetes and malignancy. In addition, disease damage, particularly renal failure, increases the risk of toxicity. Improvements in disease management should include the increased awareness of treatment-related toxicity and its prevention.
authors.affiliation: Renal Immunobiology, Division of Immunity and Infection, University of Birmingham, Birmingham, UK.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Turnbull
authors.forename: Lorraine
authors.initials: L
authors.lastname: Harper
mesh_terms: D000328:Adult; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D015267:Churg-Strauss Syndrome / Q000150:complications / Q000628:therapy; D003520:Cyclophosphamide / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000628:therapy; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007239:Infections / Q000139:chemically induced* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000009:adverse effects*; D014657:Vasculitis / Q000150:complications / Q000628:therapy*; D055815:Young Adult
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone